tbuckley/cabot-search huggingface dataset:
Spontaneous Retropharyngeal Hematoma
Authors: Noah Ditkofsky, Tarek Hanna
Journal: New England Journal of Medicine (2016)

A 56-year-old man presented to the emergency department with a 5-hour history of throat swelling and pain and difficulty breathing that was exacerbated by supine positioning; he had not had any obvious antecedent trauma. His medical history included prostate cancer, hypertension, hyperlipidemia, deep-vein thrombosis, and stroke. Medications included warfarin (presumably for deep-vein thrombosis), antihypertensive agents, and a statin. He was afebrile, and the physical examination was notable for minor swelling of the posterior oropharynx. Laboratory studies revealed a normal white-cell count, an international normalized ratio of more than 11, a prothrombin time of more than 120 seconds, and an activated . . .
A POTENT VASOCONSTRICTOR KISSPEPTIN-10 ACCELERATES ATHEROSCLEROTIC PLAQUE PROGRESSION AND INSTABILITY
Authors: Kengo Sato, Remina Shirai, Tomoyuki Yamashita, Hayami Yoshizawa, Taka-Aki Matsuyama, Shinji Koba, Takuya Watanabe
Journal: Journal of the American College of Cardiology (2016)
Peritoneal Dialysis in the Treatment of Boric Acid Poisoning
Authors: William E. Segar
Journal: New England Journal of Medicine (1960)

THE purpose of this communication is to demonstrate that peritoneal dialysis can be performed safely and successfully on small infants and that the removal of boric acid and, presumably, other water-soluble toxins can be effected more efficiently by this technic than by exchange transfusion.Three newborn infants with severe boric acid poisoning were recently studied after transfer from a neighboring hospital, where, through error, their milk-feeding mixture and drinking water had been prepared from a solution of boric acid.Case ReportsCase 1. J.G., a 5-day-old male infant weighing 3.8 kg. (8 pounds, 8 ounces), was admitted to the James . . .
A9.06 Analysis of cell-specific interferon response in systemic lupus erythematosus using a novel flow cytometric assay
Authors: YM El-Sherbiny, MY Md Yusof, EM Hensor, A Psarras, A Mohamed, M Wittmann, P Emery, EM Vital
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background and objectives</h3> Type I interferons (IFN-I) have diverse effects on immune cell populations in SLE, Measuring IFN-I using whole blood interferon-stimulated gene (ISG) expression does not completely explain clinical features of SLE. Objective: develop a cell-specific assay using a surface protein encoded by an ISG (<i>BST2</i>). This would allow convenient analysis of IFN response in individual populations to improve immunophenotyping of SLE patients. <h3>Materials and methods</h3> PBMCs from 133 SLE patientsand 19 healthy controls (HC) were analysed by flow cytometry for cell surface BST2 protein on each immune cell subset. Cells were FACS-sorted into naïve and memory B-cells, plasmablasts, CD3<sup>+</sup> T-cells, NK-cells and monocytes in 12 SLE patients and 16 healthy controls. Expression of <i>BST2,</i> as well as 32 other&nbsp;ISGs, were measured using qPCR. <h3>Results</h3> Analysis of sorted cells confirmed that surface BST2 is a valid cell-specific IFN assay. <i>BST2</i> expression correlated with BST2 surface protein within each immune subset: naïve B-cells (r = 0.63, p = 0.009); memory B-cells (r = 0.78, p &lt; 0.001); plasmablasts (r = 0.58, p = 0.018);NK cells (0.63, p = 0.008);T-cells (r = 0.61, p = 0.012); monocytes (r = 0.47, p = 0.064). We next used surface BST2 to compare IFN activity of each subset with clinical features in 133 patients. A significant correlation between the PBMC 33-gene IFN score and surface BST2 for each cell subset (all p &lt; 0.001) confirmed validity of BST2 biomarker in this larger population as a measure of overall IFN status. BST2 was significantly higher in SLE than HC on naïve and memory B-cells (p = 0.004, p = 0.003), plasmablasts (p = 0.047), T cells (p = 0.043), but not different on monocytes (p = 0.406). Association of disease activity (total BILAG) with BST2 on naïve and memory B-cells (Tau-a = 0.23 and 0.22 respectively) was substantive and approximately twice as strong as monocytes and T-cells (Tau-a = 0.12 and 0.14). A similar pattern was seen for anti-dsDNA titre, with no association with monocyte BST-2 (Tau-a = 0.07) but a substantive association for memory B cell BST-2 (Tau-a = 0.18). <h3>Conclusion</h3> IFN-I response differs in cell subsets. This can be measured in a fast, cost-effective, convenient assay using flow cytometric analysis of surface BST2. Our results show that IFN activity measured on B cells is more clinically relevant than on other cell populations.
A5.16 miRNA expression profile in Bulgarian patients with rheumatoid arthritis compared to patients with osteoarthritis and healthy controls in regard to their use as biomarkers in the clinical practice
Authors: R Shumnalieva, D Kachakova, S Monov, R Kaneva, Zl Kolarov, R Rashkov
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background and Objectives</h3> The pathogenesis of rheumatoid arthritis (RA) is still unknown. Recent data suggest that micro-ribonucleic acids (microRNAs) and their targets are involved in the inflammatory process and may perpetuate the chronic joint involvement. The aim of the study is to compare the expression of certain microRNA in peripheral blood and synovial fluid in Bulgarian patients with RA in relation to their clinical picture and laboratory data. The expression profile of RA samples was compared with samples from patients with osteoarthritis (OA) and healthy controls (HCs). The chosen microRNAs were analysed in regard to their use as biomarkers for disease activity and progression. <h3>Materials and Methods</h3> 80 RA patients according to the 1987 ACR criteria (17 drug naïve, 29 corticosteroid naïve, 31 DMARDs naïve, 31 biologic naïve patients), 20 OA patients and 20 healthy controls were included in the study. Paired peripheral blood (PB) and synovial fluid (SF) samples were used for detecting miRNA expression. The PB samples were collected in PAX gene tubes and SF samples were collected and stored with RNeasy Protect Cell Mini kit (according to manufacturer's protocol). MicroRNAs from the samples were isolated and PCR (SYBR green technology) was further performed. The results were analysed in regard to the clinical picture including radiological stage, the laboratory data for disease activity and the immunological status. <h3>Preliminary results </h3> Our preliminary data showed differences in the expression profile of the chosen miRNAs between PB and SF in RA patients compared to OA and HCs. The miRNA profile was related to the clinical picture in these patients as well as to their immunological status. The further statistical analysis will show if these microRNAs can be used as biomarkers in RA and future studies of the functional rule (microRNA targets) will reveal new aspects of RA pathogenesis. <h3>Conclusions</h3> The relationship between the clinical picture of RA patients, the laboratory data including immunological status as ANA positivity, RF subclasses, aCCP positivity and DAS 28 score with the expression profile of microRNAs in body fluids will eventually show if these microRNAs can be used as blood/synovial fluid based biomarkers in the clinical practice for patients with RA early in the disease course. This is the first miRNA study in Bulgarian patients with rheumatic diseases.
CÁNCER GÁSTRICO PRECOZ: ¿ES POSIBLE SU DIAGNÓSTICO EN NUESTROS HOSPITALES CON LOS MEDIOS TÉCNICOS DE QUE DISPONEMOS?
Authors: JJ Vila, B González De La Higuera, D Ruiz-Clavijo, A Iriarte, C Prieto, MA Casi, J Urman, F Bolado, I Fernández-Urién, FJ Jiménez
Journal: Endoscopy (2014)

Introducción: El diagnóstico de cáncer gástrico precoz (CGP) en nuestro medio está considerado un hallazgo casual por limitaciones técnicas y formativas.
The Palate and Down's Syndrome
Authors: Burton L. Shapiro, Robert J. Gorlin, Robert S. Redman, Heinz H. Bruhl
Journal: New England Journal of Medicine (1967)

ALMOST from the time of its first description Down's syndrome (mongolism) has been associated with abnormal palatal shape and size – so much so that Benda1 included the palate among 9 areas of developmental retardation most conspicuous in mongolism, and Oster2 described high narrow palate as 1 of 10 cardinal signs of Down's syndrome. Yet these anomalies have received relatively little attention. In nearly every clinical study in which palatal shape has been noted, observations have been nonmetrical and accordingly susceptible to subjective error. In the present series metrical information was obtained on palates of patients with mongolism and compared . . .
Reply to Corbett &amp; Cameron
Authors: L. Lim, Y. Chan, K. Ho, K. Yeoh
Journal: Endoscopy (2011)

We would like to thank Corbett & Cameron for their letter. Our study [1] was an observational study with prospectively collected data. It showed that urgent endoscopy was associated with lower mortality in high-risk but not low-risk nonvariceal upper gastrointestinal bleeding. Our findings are consistent with the recommendations of an international consensus [2] which states that there is no additional benefit conferred by urgent endoscopy (< 12 hours) compared with early endoscopy (> 12 hours) in unselected nonvariceal upper gastrointestinal bleeding. In the majority of our cohort, urgent endoscopy was not associated with decreased mortality. Endoscopy within 13 hours was associated with lower mortality only in a very small subset of patients with severe nonvariceal upper gastrointestinal bleeding, as triaged using the Glasgow-Blatchford score.
Abstract B3: A nested case control study of the polymorphic locus -202 in the promoter region of the IGFBP-3 gene and breast cancer risk
Authors: Debora Macis, Patrick Maisonneuve, Hariett Johansson, Valentina Aristarco, Aliana Guerrieri-Gonzaga, Nicole Rotmensz, Barbara Santillo, Giacomo Gucciardo, Giuseppe D'Aiuto, Marco Rosselli del Turco, Alberto Costa, Umberto Veronesi, Andrea Decensi, Bernardo Bonanni
Journal: Clinical Cancer Research (2010)

Abstract Background: The Insulin-like Growth Factors (IGFs) system has been shown to have an important role in breast carcinogenesis due to its involvement in the regulation of cell proliferation, differentiation and apoptosis. Several studies have found an association between serum concentration of IGF-I and IGFBP-3 - its major binding protein - and breast cancer risk. A single nucleotide polymorphism in the promoter region of the IGFBP-3 gene (rs2854744), located at position -202 from the transcription start site, results in reduced promoter activity and decreased IGFBP-3 levels. Some evidence of an association between this polymorphism and breast cancer risk has been reported. Methods and results: We conducted a nested case-control study within the Italian Tamoxifen Chemoprevention Trial, a phase III double-blind placebo-controlled multicentric prevention trial involving 5,408 hysterectomized women aged 35–70 years, who had received either tamoxifen 20 mg/day or placebo for 5 years. After an initial median follow-up of 81.2 months, 79 subjects were diagnosed with breast cancer. Forty-six patients (cases) consented a blood withdrawal as well as 136 controls without breast cancer, randomly selected and matched for age (±2 years), randomization date (±6 months) and participating center. We genotyped case and control subjects for IGFBP-3 -202A&amp;gt;C with a Taqman real time PCR method for allelic discrimination (Applied Biosystems). The IGFBP-3 -202A&amp;gt;C genotype frequencies for AA, AC, CC were 46%, 43% and 11% respectively in breast cancer cases and 31%, 48%, 21% in controls. We found a significant trend for a higher frequency of A allele within breast cancer cases compared to unaffected control subjects (Ptrend=0.04). We observed an odds ratio of 0.35 (95% CI 0.12–1.02) for breast cancer in subjects with CC compared to AA genotype, while no further association was found after stratifying for age and treatment group. Conclusions: We showed that in the analyzed population within the Italian Tamoxifen Chemoprevention Trial, the genotype frequencies for the IGFBP-3 -202 A allele were higher in breast cancer cases compared to unaffected control subjects at variance with other observations. These results suggest that variation at the polymorphic locus -202 in the IGFBP-3 gene might have an influence on breast cancer risk, although further studies are mandatory to clarify the direction of this association and the possible biological meaning and clinical implications. Citation Information: Clin Cancer Res 2010;16(7 Suppl):B3
SP0037 Two difficult SLE patient cases
Authors: R. Derksen, K.M.A.C. Luijten, R.D.E. Fritsch-Stork
Journal: Annals of the Rheumatic Diseases (2012)

<b>Case 1</b> is a woman who was referred for pregnancy counselling in 1993 (age 29 years). She had antiphospholipid syndrome (APS) based on a history with DVT, 2 early spontaneous abortions and positive serology. There was obesity (BMI 40,5), livedo reticularis, hypertension and renal insufficiency. Antinuclear, anti-dsDNA, anticardiolipin antibodies (IgG) and Lupus anticoagulant were present. Renal biopsy showed mesangioproliferative changes with ischemia and vascular abnormalities compatible with malignant hypertension. Treatment with aspirin and antihypertensive drugs was started. In 1995 she had an ischemic stroke with aphasia. Aspirin was replaced by oral anticoagulants. Five months later she developed glomerulonephritis (biopsy: mesangioproliferative glomerulonephritis) and treatment with high dose prednisone was started. In 2001 she had a proximal DVT despite adequate anticoagulation (INR 4.7), followed by subdural and subarachnoidal cerebral bleeding. Shortly after this episode recurrent DVT occurred. Treatment with oral anticoagulants was stopped and continuous anticoagulation with LMWH was given. After 7 years on this treatment she had another ischemic cerebral infarction. Aspirin was added to the medications. Over the last few years no recurrent thrombosis occurred. Points for discussion will be renal manifestations and treatment of thrombotic APS. <b>Case 2</b> is a woman diagnosed in 1995 with SLE (arthritis, SCLE, antinuclear, anti-dsDNA and antiSm-Ab) at age 24. In 2003 she give birth to a healthy daughter after an uncomplicated pregnancy. Seven years later she suddenly experienced episodic visual complaints, transient difficulties with speaking and headaches. Platelet count: 10.10<sup>9</sup>/L. Points for discussion: differential diagnosis of thrombocytopenia in SLE. <h3>Disclosure of Interest</h3> None Declared
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Authors: Brian J. Druker, Moshe Talpaz, Debra J. Resta, Bin Peng, Elisabeth Buchdunger, John M. Ford, Nicholas B. Lydon, Hagop Kantarjian, Renaud Capdeville, Sayuri Ohno-Jones, Charles L. Sawyers
Journal: New England Journal of Medicine (2001)

BCR-ABL is a constitutively activated tyrosine kinase that causes chronic myeloid leukemia (CML). Since tyrosine kinase activity is essential to the transforming function of BCR-ABL, an inhibitor of the kinase could be an effective treatment for CML.
Effects of Admission to a Teaching Hospital on the Cost and Quality of Care for Medicare Beneficiaries
Authors: Donald H. Taylor, David J. Whellan, Frank A. Sloan
Journal: New England Journal of Medicine (1999)

We studied the effects of admission to a teaching hospital on the cost and quality of care for patients covered by Medicare (age, 65 years old or older). We used data from the National Long Term Care Survey and merged them with Medicare claims data. We selected the first hospitalization for hip fracture (802 patients), stroke (793), coronary heart disease (1007), or congestive heart failure (604) occurring between January 1, 1984, and December 31, 1994, and calculated all Medicare payments for inpatient and outpatient care during the six-month period after admission. Survival was assessed through 1995. Hospitals were classified as major or minor teaching hospitals (with minor hospitals defined as those in which the number of residents per bed was less than the median number for all teaching hospitals) or as private nonprofit, government (i.e., public), or private for-profit hospitals.
“SILENT” ATRIAL FIBRILLATION BURDEN IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY
Authors: Ankur Kalra, Pranay Rao, Amit Sharma, Shreya Bhandari, Ross Garberich, Deepa McGriff, Susan Casey, Raed Abdelhadi, JoEllyn Abraham, Jay Sengupta, Barry Maron
Journal: Journal of the American College of Cardiology (2015)
Phase II trial of multiagent chemotherapy combined with Y-90 microsphere selective internal radiation therapy (chemo-SIRT) in patients with colorectal cancer liver metastases
Authors: K. L. Pennington, S. A. Gulec, D. Breutman, R. Hostetter, J. Wheeler, D. Schwartzentruber
Journal: Journal of Clinical Oncology (2008)

15011 Background: Concurrent chemotherapy and radiation in colorectal cancer(CRC) can improve outcome of local or regional disease. This study is an attempt to derive a similar benefit using chemotherapy and a novel method of radiation therapy for patients with CRC metastatic to liver. Yttrium-90 (Y-90) microsphere selective internal radiation treament (SIRT) has proven to be a safe and effective mode of radiation delivery technique in patients (pts) with CRCLM as a single modality and with 5-FU and FUDR. This is a phase II trial of Y-90 microspheres and concurrent multiagent chemotherapy for management of CRCLM. This study is designed to measure response using updated methods of measurements based on pet scan and computer modeling as well as common criteria. Assessment of toxicity, especially hepatotoxicity and myelotoxicity, is the second major objective. Methods: 20 patients with disease limited predominantly to the liver were recruited for the study. Pre-treatment studies included a liver-protocol PET-CT, angiogram and 99mTc-MAAA (macroaggregaated albumin) imaging. Chemotherapy (Fol-Fox or Fol-Firi) was planned every 2 weeks for 8 cycles. SIRT with Y-90 resin microspheres (Sirtex Medical, Wilmington, MA) was administered on day 2 of the first chemotherapy course either lobar or whole-liver fashion. Administered activity of Y-90 microspheres ranged from 0.2 to 3.8 GBq (mean 1.8 GBq). CEA levels, tumor anatomic volume (VA) and functional volume (VF) by FDG-PET/CT were used to determine tumor response. Results: 20 patients have been treated and 19 are evaluable. 13 patients were chemo-naive, 7 had prior chemo. 3 received whole liver, 16 received lobar, one segmental SIRT. 16/19 patients had a VF decrease of >90% and the average decrease for 3 was 56%. 15/16 pts with an elevated cea had >50% decline. 12/19 pts had > 50% reduction in VA. 4 patients have undergone surgery subsequent to chemo-SIRT. 4 pts required hospitalization due to SAE, 1 with neutropenic fever. 2 pts had grade 3 sphere-induced gi ulcer. Conclusions: Chemo-SIRT with modern chemotherapy results in a high objective response rate with acceptable toxicity and deserves further study. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Sirtex Medical Inc Sirtex Medical Inc
THE CARDIAC BIOMARKERS IN CHILDREN WITH CARDIOMYOPATHY MULTICENTER STUDY: PRELIMINARY RESULTS FOR PEDIATRIC HYPERTROPHIC CARDIOMYOPATHY
Authors: Steven Lipshultz, James Wilkinson, Ling Shi, Jeffrey Towbin, Charles Canter, Daphne Hsu, Steven Webber, Paul Kantor, Melanie Everitt, Elfriede Pahl, John Jefferies, Joseph Rossano, Linda Addonizio, Debra Dodd, Stephanie Ware, Kimberly Molina, Steven Colan
Journal: Journal of the American College of Cardiology (2016)
Abstract 143: Breast cancer incidence rate in american women started to increase: Trend analysis from 2000 to 2009.
Authors: Ningqi Hou, Dezheng Huo
Journal: Cancer Research (2013)

Abstract Background: Recent report showed that breast cancer incidence rate in the US stabilized after a sharp reduction in 2002 and 2003. It is important to continue monitoring breast cancer incidence rates according to age group, race/ethnicity, estrogen receptor (ER), and tumor stage. Methods: Age-standardized breast cancer incidence rates were calculated using data from the Surveillance, Epidemiology, and End Results (SEER) 18 registries from 2000 to 2009, among 677,774 female breast cancer patients aged 20 and above. Jointpoint regression models were used to fit a series of joined straight lines on a log scale to the trends of annual age-standardized rates. Results: The overall breast cancer incidence significantly increased for non-Hispanic black from 2005 to 2009 (annual percentage change, APC =2.0%, p=0.01) and Asian/Pacific Islanders from 2000 to 2009 (APC 1.2%, p=0.02). Since 2004, incidence rates in women age 40-49 significantly increased for all racial/ethnic groups (overall APC = 1.1%, p=0.001). Incidence rate of carcinoma in situ significantly increased in all racial/ethnic groups (APC ranges from 2.3%-3.0%, p&amp;lt;0.005) and localized breast cancer incidence significantly increased in non-Hispanic blacks (APC=1.3%, p=0.004) and Asian (APC=1.2%, p=0.03). ER positive breast cancer significantly increased in almost all age/race sub-groups after 2005 (APC by race: non-Hispanic white 1.5%, non-Hispanic black 4.3%, Asian/Pacific Islander 1.7%, and Hispanic 1.8%, p-values&amp;lt;0.05), while ER negative breast cancer decreased in most sub-groups (APC by race: non-Hispanic white -3.9%, non-Hispanic black -3.7%, Asian/Pacific Islander -1.5%, and Hispanic -4.3%, p-values&amp;lt;0.05). Conclusions: Recent incidence of breast cancer appears to be increasing in certain subgroups, including non-Hispanic black, Asian/Pacific Islanders, women 40-49 years old, low-stage breast cancer, and estrogen-receptor positive breast cancer. These changes are unlikely due to mammography screening rate that has remained stable in recent years, but may be partially explained by the transition from film to digital mammography, which has higher sensitivity to detect breast cancer, especially young-onset breast cancer. It deserves further investigation on why the rate of estrogen receptor negative breast cancer declined. Citation Format: Ningqi Hou, Dezheng Huo. Breast cancer incidence rate in american women started to increase: Trend analysis from 2000 to 2009. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 143. doi:10.1158/1538-7445.AM2013-143